# US 2013/0156857 A1 · Pharmaceutical Compositions Containing Diacerein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156857 A1
- Document ID: US20130156857A1
- Status: Published application
- Kind: A1
- Application number: 13/768,844
- Filed: 2013-02-15
- Published: 2013-06-20
- Earliest claimed: 2008-10-28
- Assignees: TWi Biotechnology, Inc.
- Inventors: Danchen Gao; Jen-Sen Wu; Wei-Shu Lu; Shouchiung Chen; Pei-Chun Kuo; Chih-Ming Chen
- Web page: https://patentgrep.com/patent/US20130156857A1

## CPC

- A61K 31/235: having an aromatic ring attached to a carboxyl group
- A61K 9/146: {with organic macromolecular compounds}
- A61K 9/1676: {having a drug-free core with discrete complete coating layer containing drug (adsorbates of liquid drug formulations on inert powders without simultaneous granulation step A61K9/141; with further drug-free outer coating A61K9/5078; drug conjugated to non-active particles A61K47/6921)}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/284: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone}
- A61K 9/2846: {Poly(meth)acrylates}
- A61K 9/2853: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)}
- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/5078: {with drug-free core}
- A61K 47/6951: {using cyclodextrin (cyclodextrins used as simple excipients A61K47/40)}
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A once-daily controlled-release formulation of diacerein for treating inflammatory or autoimmune diseases or their complications, with reduced adverse side effects and methods of treating such diseases are disclosed.

## Claims

### Claim 1

A once-daily controlled-release formulation of diacerein for treating inflammatory diseases, autoimmune diseases or their complications with reduced adverse side effects, comprising an active layer, a sustained-release film layer, and a delayed-release film layer, wherein said sustained-release film layer comprises an ethyl cellulose polymer, povidone, triethyl citrate and talc, and wherein said delayed-release film layer comprises an Eudragit® polymer, triethyl citrate and talc.

### Claim 2 (depends on 1)

The controlled-release formulation according to claim 1, wherein the formulation is a membrane-controlled formulation, matrix formulation or osmotic pump formulation.

### Claim 3 (depends on 1)

The controlled-release formulation according to claim 1, wherein the formulation comprises a surfactant, acidifying agent or a buffering agent.

### Claim 4 (depends on 1)

The controlled-release formulation according to claim 1, wherein the particle size of diacerein is less than 2000 μm.

### Claim 5 (depends on 1)

The controlled-release formulation according to claim 1, wherein the diacerein is presented as an amorphous state in a solid carrier.

### Claim 6 (depends on 1)

The controlled-release formulation according to claim 1, wherein the diacerein is formed as a complex with cyclodextrins.

### Claim 7 (depends on 1)

The controlled-release formulation according to claim 1, wherein the diacerein is crystalline.

### Claim 8 (depends on 1)

The controlled release formulation according to claim 1 wherein a formulation containing 50 mg diacerein maintains the plasma concentration of rhein above the concentration of 1 mg/L for more than 12 hours in humans, when orally administered to a human patient who has reached the steady state condition

### Claim 9 (depends on 1)

The controlled release formulation according to claim 1 wherein a formulation containing 100 mg diacerein maintains the plasma concentration of rhein above the concentration of 2 mg/L for more than 12 hours in humans, when orally administered to a human patient who has reached the steady state condition.

### Claim 10 (depends on 1)

A method of treating inflammatory diseases, autoimmune diseases or their complications comprising administering to a subject in need thereof a once-daily controlled-release formulation of diacerein according to claim 1, wherein said method results in fewer adverse side effects as compared to administering immediate release formulations of diacerein.

### Claim 11 (depends on 10)

The method according to claim 10, wherein said adverse side effect is diarrhea.

### Claim 12 (depends on 10)

The method of claim 10, wherein the controlled-release formulation is administered to treat type I/type II diabetes or osteoarthritis.

### Claim 13 (depends on 10)

The method of claim 10, wherein the controlled-release formulation is administered to treat complications from type I/type II diabetes.

### Claim 14 (depends on 10)

The method of claim 10 wherein the complications from type I/type II diabetes are nephropathy, retinopathy, neuropathy or foot ulcers.

### Claim 15 (depends on 1)

A once-daily controlled-release formulation according to claim 1 comprising a first active of diacerein and a second active ingredient for treating inflammatory diseases, autoimmune diseases or their complications.

### Claim 16 (depends on 15)

The controlled-release formulation according to claim 15, wherein said second active ingredient is an angiotensin converting enzyme inhibitor, a angiotensin II receptor blockers, a antihyperglycemic drug, or a Non-steroidal anti-inflammatory drug.

### Claim 17 (depends on 1)

The controlled-release formulation according to claim 1 comprising about 20.0% by weight of diacerein, about 20.0% by weight of hydroxymethylpropylcellulose, about 57.0% by weight of mannitol, about 2.0% by weight of povidone and about 1.0% by weight of magnesium stearate.

### Claim 18 (depends on 1)

The controlled-release formulation according to claim 1 comprising about 20.0% by weight of diacerein, about 40.0% by weight of hydroxymethylpropylcellulose, about 37.0% by weight of mannitol, about 2.0% by weight of povidone and about 1.0% by weight of magnesium stearate.

### Claim 19 (depends on 1)

The controlled-release formulation according to claim 1, wherein said active layer comprises between about 40.0% and about 50.0% by weight of microcrystalline cellulose, between about 20.0% and about 30.0% by weight of diacerein, between about 2.0% and about 5.0% by weight of povidone and between about 20.0% and about 30.0% by weight of mannitol.

### Claim 20 (depends on 21)

The controlled-release formulation according to claim 21, wherein said active layer comprises about 50.0% by weight of microcrystalline cellulose, about 25.0% by weight of diacerein, about 2.0% by weight of povidone and about 23.0% by weight of mannitol.
